Purpose

Photobiomodulation therapy (PBMT) involves applying non-ionizing forms of light from sources including lasers, LEDs, and broadband light, in the visible and near infrared spectrum, to the body to enhance performance, stimulate healing, modulate recovery, and improve health. The investigators will conduct a single-blinded randomized-control trial with sham control to investigate the effectiveness of providing PBMT in a military population, translating this cutting-edge research to application in the operational setting.

Condition

Eligibility

Eligible Ages
Between 18 Years and 45 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  1. Active-duty military personnel, government civilians, and government contractors 2. Between the ages of 18-45 years old (inclusive) 3. Ability to read and understand English language 4. Willingness and ability to commit to study procedures, including study intervention and follow-up

Exclusion Criteria

  1. Body fat > 40% 2. Weight exceeds 300lbs 3. Height exceeds 7ft 3in 4. > 10% of full body coverage of tattoos 5. Cardiovascular disease requiring medical management 6. Currently utilizing a pacemaker 7. Currently utilizing select medications (e.g., statins, diuretics, antihypertensive agents) 8. Currently utilizing medications associated with sensitivity to heat or light (e.g., amiodarone, chlorpromazine, doxycycline, hydrochlorothiazide, nalidixic acid, naproxen, piroxicam, tetracycline, thioridazine, voriconazole) 9. Currently undergoing treatment for a brain-related injury 10. Diagnosis of autoimmune diseases 11. Diagnosis of porphyria (light induced allergy) or photosensitive eczema 12. Diagnosis of Cancer 13. Diagnosis of epilepsy and/or being seizure prone 14. Diagnosis of diabetes 15. Diagnosis of Lupus Erythematosus 16. Diagnosis of retinal disease 17. Uncontrolled thyroid disease (known problem with no medical management) 18. Cirrhosis of the liver 19. Impaired blood clotting (from medication or underlying condition) 20. Photophobia 21. Albinism/achromasia 22. Currently pregnant or plan to become pregnant during the study (6 weeks) 23. Currently participating in any other intervention-based research studies other than protocol FWR20220097H that may confound results.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Intervention Model Description
Participants will have two 3-week periods of treatment with a washout week in-between treatment. Participants will be randomized to either sham PBM treatment or active PBM treatment first.
Primary Purpose
Basic Science
Masking
Single (Participant)
Masking Description
To prevent possible bias between the sham and active conditions, both groups will receive light filtering glasses (to control for light perception), noise-cancelling headphones, and be in a controlled temperature room.

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Active Photobiomodulation Full Body Light Bed Therapy
Active treatment will be provided via a specialized full body light bed equipped with light-emitting diodes (LEDs) emitting specific wavelengths of light. The participant will be asked to lay in the bed for a 20-minute session. Treatment will be provided 3 times a week for 3 weeks.
  • Device: NovoTHOR XL Photobiomodulation Full Body Light Bed
    Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of ~30 mW/cm^2.
  • Device: ARRC LED Photobiomodulation Full Body Light Bed
    High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of ~75 mW/cm^2.
Sham Comparator
Sham Photobiomodulation Full Body Light Bed Therapy
Sham-PBMT will be delivered in the same manner as indicated for the Active treatment process, but the devices will not be turned on. The participant will be asked to lay in a specialized full body light bed equipped with light-emitting diodes (LEDs) for a 20-minute session. Sham-PBMT Treatment will be provided 3 times a week for 3 weeks.
  • Device: NovoTHOR XL Photobiomodulation Full Body Light Bed
    Low powered full-body photobiomodulation light bed therapy will be administered via the NovoTHOR XL light therapy bed which emits an average irradiance of ~30 mW/cm^2.
  • Device: ARRC LED Photobiomodulation Full Body Light Bed
    High powered full-body photobiomodulation light bed therapy will be administered via the ARRC LED light therapy bed which emits an average irradiance of ~75 mW/cm^2.

Recruiting Locations

Wright Patterson Air Force Base
Beavercreek, Ohio 45324
Contact:
Margaret E Hollander
703-863-4124
Mhollander@Genevausa.org

More Details

NCT ID
NCT06403644
Status
Recruiting
Sponsor
United States Air Force Research Laboratory

Study Contact

Margaret E Hollander
7038634124
Mhollander@Genevausa.org

Detailed Description

In addition to assessing the efficacy of whole-body PBMT in comparison to sham therapy, the human subjects PBM study conducted encompasses a comprehensive data collection endeavor aimed at evaluating PBMT's impact on general wellness. Using a single-blinded randomized control trial design, participants are assigned to different treatment groups and subjected to PBMT or sham treatments over specified periods. Randomization ensures unbiased assignment to treatment groups, and participants are blinded to their assigned study arm until the conclusion of the final study visit. Detailed treatment protocols are followed, including precautions to minimize bias between active and sham treatments. Data collection includes an extensive array of both subjective and physiological measures, encompassing tools such as the Defense and Veteran's Pain Rating Scale (DVPRS), Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), heart rate monitors, blood samples, and saliva samples. Additionally, this study investigates the differences between high-power PBMT (~70mW/cm2) and low-power PBMT (~30mW/cm2) by a secondary randomization of participants into one of two commercial PBMT light beds (either the NovoTHOR or ARRC LED). The study is conducted over an 8-week period and separated into two arms. Participants that meet final eligibility criteria will be randomized to a study arm following informed consent using a computer-generated randomization model. Participants will first be randomized (1:1) to a high-power PBM (ARRC-LED) or low-power PBM (NovoTHOR) treatment group. Then participants will subsequently be randomized (1:1) to a treatment schedule (either sham or active treatment first). The initial week of the study consists of a washout week in which baseline data is collected. In Part 1 (Weeks 2-4), participants undergo photobiomodulation treatment sessions or sham photobiomodulation treatment sessions lasting 20 minutes, occurring 3 times a week for 3 weeks. Following Part 1, Week 5 consists of an additional washout period. During this 1-week period, participants will continue daily study procedures, including questionnaires, saliva collection, and wearing the Oura Ring, but will not receive sham or active PBMT. In Part 2 (Weeks 6-8), participants will resume treatment sessions crossing over into the other condition (either sham or active PBMT), also lasting 20 minutes and occurring 3 times a week for 3 weeks. Overall, the human subjects experiment works to provide valuable insights into the practical applications and potential benefits of PBMT.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.